Welcome to our dedicated page for Immunome news (Ticker: $IMNM), a resource for investors and traders seeking the latest updates and insights on Immunome stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Immunome's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Immunome's position in the market.
Immunome, Inc. (IMNM) will be presenting at the 2024 Bank of America Healthcare Conference. The President and CEO, Clay Siegall, will present on May 15, 2024. Interested parties can access the live webcast on the company's website.
Immunome, Inc. (Nasdaq: IMNM) has appointed Kinney Horn as Chief Business Officer, bringing extensive experience in life sciences corporate and business development to the company. With the recent acquisition of AL102, Immunome is now a clinical stage company, aiming to enhance its development capabilities and expand its portfolio of targeted cancer therapies. Mr. Horn's successful track record in strategic partnerships will play a important role in Immunome's growth.